Log in to search using one of your social media accounts:

 

Silicone Gel for Preventing Hypertrophic Scars and Keloids Silicone Gel for Preventing Hypertrophic Scars and Keloids
A new review explores the effectiveness of prevention by silicone gel material for hypertrophic scars and keloids.Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 17, 2017 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news

What Is the Mole Alphabet Again?
Discussion Melanocytic nevi or moles are pigmented nevi that are extremely common in children with ~ 98% of Caucasian children having at least 1 by early childhood. They are caused by benign melanocyte growth. These nevi reside in the epidermis or dermis, whereas regular melanocytes that produce general skin pigmentation reside in the basal layer. Moles are very often uniform – they basically look the same within the individual. The number of moles increases in the first 2-3 decades of life. Teens having 15-25 moles. They can also disappear. Congenital melanocytic nevi are found in 1-3% of newborns and grow in prop...
Source: PediatricEducation.org - March 27, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

[Report] Regeneration of fat cells from myofibroblasts during wound healing
Although regeneration through the reprogramming of one cell lineage to another occurs in fish and amphibians, it has not been observed in mammals. We discovered in the mouse that during wound healing, adipocytes regenerate from myofibroblasts, a cell type thought to be differentiated and nonadipogenic. Myofibroblast reprogramming required neogenic hair follicles, which triggered bone morphogenetic protein (BMP) signaling and then activation of adipocyte transcription factors expressed during development. Overexpression of the BMP antagonist Noggin in hair follicles or deletion of the BMP receptor in myofibroblasts prevente...
Source: ScienceNOW - February 16, 2017 Category: Science Authors: Maksim V. Plikus Source Type: news

[Perspective] Fibroblasts become fat to reduce scarring
Following cutaneous injury in adult mammals, one of two outcomes can occur: successful healing with scar formation or nonsuccessful healing and a chronic wound. In humans, scar formation can be classified in terms of “normal scar” formation versus pathologically increased fibrosis, as seen in hypertrophic scarring and keloids (1). Although scarring does not look or function like surrounding unwounded skin, it allows one to survive injury (and hence, procreate). However, extensive scarring from burns and conditions such as scleroderma or epidermolysis bulosa are not only unsightly but also contribute to substant...
Source: ScienceNOW - February 16, 2017 Category: Science Authors: Charles K. F. Chan Tags: Tissue Regeneration Source Type: news

Our expert on how to heal red and lumpy wounds  
Maggie Hendey from the Isle of Wight asks Dr Scurr her husband's scar, which he has from a triple heart surgery. Our expert reveals a range of treatments for keloid- and hypertrophic scars. (Source: the Mail online | Health)
Source: the Mail online | Health - October 3, 2016 Category: Consumer Health News Source Type: news

Stopping scars before they form
Most people start racking up scars from an early age with scraped knees and elbows. While many of these fade over time, more severe types such as keloids and scars from burns are largely untreatable, and can carry the stigma of disfigurement. Now scientists are developing new compounds that could stop scars from forming in the first place. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 21, 2016 Category: Science Source Type: news

Keloid
Title: KeloidCategory: Diseases and ConditionsCreated: 1/25/2000 12:00:00 AMLast Editorial Review: 8/11/2016 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - August 11, 2016 Category: Dermatology Source Type: news

Sensus Healthcare, Inc. Names Anthony Petrelli to its Board of Directors
BOCA RATON, Fla., Aug. 2, 2016 -- (Healthcare Sales & Marketing Network) -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial ra... Devices, Dermatology, Oncology, Personnel Sensus Healthcare, superficial radiation therapy, skin cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 2, 2016 Category: Pharmaceuticals Source Type: news

E! series Botched shows man having keloid lumps removed from his ears
Trevor met with LA-based surgeons Dr. Terry Dubrow and Dr. Paul Nassif on Tuesday night's episode of the E! reality series Botched, during which they removed the scar tissue from his lobes. (Source: the Mail online | Health)
Source: the Mail online | Health - June 29, 2016 Category: Consumer Health News Source Type: news

Sensus Healthcare closes $11m IPO
Sensus Healthcare (NSDQ:SRTSU) said today it closed its initial public offering, raising $11 million through the sale of 2.3 million units at $5.50 each. The offering included a fully-exercised underwriters option of an additional 300,000 units at the IPO price, Sensus said. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus makes low-energy photon X-ray systems for treating non...
Source: Mass Device - June 8, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Funding Roundup Initial Public Offering (IPO) Radiosurgery Sensus Healthcare LLC Source Type: news

Sensus Healthcare prices $11m IPO
Sensus Healthcare (NSDQ:SRTSU) priced an $11 million initial public offering yesterday, saying it plans to float 2 million shares at $5.50 apiece starting today. Boca Raton, Fla.-based Sensus said the offering, expected to close June 8, also includes a 300,000-unit over-allotment option for the IPO’s underwriters. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus mak...
Source: Mass Device - June 3, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Initial Public Offering (IPO) Radiosurgery Wall Street Beat Sensus Healthcare LLC Source Type: news

Man with keloid scarring and huge growths on face is desperate to get rid of them
Keenan Patton, from Chicago, has suffered with keloids – areas of fibrous tissue that form over scar tissue or an injury - since he was a teenager. He is now undergoing radiation treatment to remove them. (Source: the Mail online | Health)
Source: the Mail online | Health - March 1, 2016 Category: Consumer Health News Source Type: news

Intralesional Cryotherapy for the Treatment of Keloid ScarsIntralesional Cryotherapy for the Treatment of Keloid Scars
How effective is this novel technique compared with other options for keloid scar treatment? Is it a viable treatment alternative? Plastic Reconstructive Surgery-Global Open (PRS Global Open) (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 23, 2015 Category: Consumer Health News Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news

Advanced Dermatology and Cosmetic Surgery (ADCS Clinics) Partners with...
Advanced Dermatology and Cosmetic Surgery, the nation’s largest dermatology practice, partners with medical device company to help treat non-melanoma skin cancers and keloids(PRWeb August 07, 2015)Read the full story at http://www.prweb.com/releases/2015/08/prweb12890618.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 7, 2015 Category: Pharmaceuticals Source Type: news

Student left with keloid scar after ear piercing as an act of teenage rebellion
18-year-old Remmie was left with a hazelnut-sized keloid scar on her ear after a bar piercing went badly wrong. The teen, who says she had hoped to stand out of the crowd, describes the scar as 'vile'. (Source: the Mail online | Health)
Source: the Mail online | Health - April 24, 2015 Category: Consumer Health News Source Type: news

Your NEJM Group Today: Incisional Keloid, Being Taught to Teach, Washington IM Opportunity (FREE)
By The Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today:NEJM Clinical Practice Center: … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 13, 2015 Category: Primary Care Source Type: news

Gene may open door for improved keloid, scar treatment
A gene that may offer a better understanding of how keloid scars develop has been discovered, potentially opening the door to improved treatment for the often painful, itchy and tender scars. The study is the first to demonstrate that an altered AHNAK gene may have a significant biological role in keloid development. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 23, 2015 Category: Science Source Type: news

Gene may open door for improved keloid, scar treatment
(Henry Ford Health System) Researchers at Henry Ford Hospital in Detroit have identified a gene that may offer a better understanding of how keloid scars develop and potentially open the door to improved treatment for the often painful, itchy and tender scars. The study is the first to demonstrate that an altered AHNAK gene may have a significant biological role in keloid development. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 23, 2015 Category: Global & Universal Source Type: news

Breakthrough drug-eluting patch stops scar growth, reduces scar tissues
A new invention provides a simple, affordable and -- most importantly -- highly effective way for patients to self-treat keloid scars. It is a special patch made from polymers fabricated into microneedles, which are loaded with the US FDA-approved scar-reducing drug, 5-fluorouracil. Self-administered by patients, the microneedles attach the patch to scar tissue and allow sustained drug-release. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 23, 2014 Category: Science Source Type: news

Keloid development: New genes identified may unlock its mystery
Previously unidentified genes that may be responsible for keloid scarring have been uncovered by researchers, a discovery that could unlock the mystery of keloid development and provide insight for more effective treatment. Keloid scars form raised, firm skin areas that may become itchy, tender, and painful. Unlike regular scars, keloids do not subside over time and often extend outside the wound site. Keloids most often occur on the chest, shoulders, earlobes (following ear piercing), upper arms and cheeks. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 29, 2014 Category: Science Source Type: news

Study: New genes identified may unlock mystery of keloid development
(Henry Ford Health System) Researchers at Henry Ford Hospital in Detroit have uncovered previously unidentified genes that may be responsible for keloid scarring, a discovery that could unlock the mystery of keloid development and provide insight for more effective treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 29, 2014 Category: Global & Universal Source Type: news

Keloid Associated With Ear Piercing
This is a classic keloidal mass, which occur in any ethic group. Because keloids can be intensely painful, they almost always require removal. (Source: Consultant Live)
Source: Consultant Live - May 2, 2013 Category: Primary Care Source Type: news

RXi completes enrolment in second Phase I trial of anti-scarring drug
Biotechnology company RXi Pharmaceuticals has announced the completion of enrolment in the second Phase I trial of RXI-109, to manage surgical and hypertrophic scars and keloids. (Source: Drug Development Technology)
Source: Drug Development Technology - February 1, 2013 Category: Pharmaceuticals Source Type: news